Innovative Industrial Properties, Inc. (IIPR) Earnings Call Transcript
August 4, 2026
Earnings Call Speaker Segments
Thanks for being on the call. With us today are Alan Gold, our Executive Chairman, Paul Smithers, our President and Chief Executive Officer, David Smith, our Chief Financial Officer, and Ben Regan, our Chief Investment Officer. I want to start by reminding all of you that certain things we say on today's conference call — including remarks about our transactions that are the subject of letters of intent — constitute forward-looking statements under the safe harbor of the Private Securities Litigation Reform Act of 1995, and they carry risks and uncertainties. Our actual results could differ materially, and for a complete discussion of the risk factors that might cause actual results to differ materially from what those forward-looking statements contain, we point you to our SEC filings, in particular our latest report on 10-K and 10-Q; we have no obligation to update or revise any forward-looking statements, whether because of new information, future events, or anything else, except as the law requires; also, on today's call we'll be discussing non-GAAP financial information, including FFO, normalized FFO, and AFFO. That information, along with reconciliations to the most directly comparable GAAP financial measure, can be found in our earnings release issued yesterday and in our 8-K filed with SEC.
I'll now pass things over to Alan. Alan? Thanks, Eli. Morning, everyone, and I appreciate you being here for our Q2 2026 earnings call. What stood out about this quarter was how well we executed right across the platform, with the IIPR team producing substantial results in portfolio management, leasing, and capital markets. We finished fully funding our $270 million commitment to IQHQ, kept seeing leasing activity throughout our cannabis portfolio, and carried out several strategic financing moves that made our balance sheet even stronger and gave us greater financial flexibility. Our IQHQ investment shows the disciplined way we deploy capital and how we keep diversifying the portfolio through opportunistic investment activity. Since we first announced this in August 2025, IQHQ has reported substantial leasing activity along with other operational progress across its portfolio; now that our funding commitment is fully complete, we still believe the quality of the underlying assets and improving life science sector fundamentals back this investment. On top of that, our team stays hard at work assessing a growing pipeline of life sciences opportunities, which puts IIPR in position to put capital to work selectively and accretively. Leasing execution stood out as another important part of the quarter. So far this year, we closed new leases at five properties adding up to roughly 389,000 square feet, all while pushing forward several other releasing efforts. Those efforts show the team's ongoing commitment to lifting occupancy, stabilizing assets, and getting the most value out of our cannabis portfolio. Just as important, we made major headway on the balance sheet. Over the quarter, we closed roughly $150 million in secured term loan financings, handled our $291 million senior debt maturity in May efficiently, and keep drawing on our ATM programs for both common and preferred equity. Above all, we successfully priced and upsized a $402.5 million exchangeable notes offering, which showed robust investor demand and gives us considerable growth capital. Alongside that transaction, we also bought back about 80.5% $5 million of our common stock. Put together, these wins show how strong our platform is: active portfolio management, steady leasing execution, and reliable access to capital at scale. With a stronger balance sheet, a distinct investment approach spanning cannabis and life sciences, and a management team with experience going back to 2018, we think we're well set up to keep building long-term shareholder value.
All right, I'll pass it over to Paul now. Appreciate that, Alan. On the federal front, cannabis reform continued to move ahead. Last month, the DEA finished its hearing about the proposal to move marijuana to a less restrictive category, from Schedule 1 to Schedule 3. Responsibility for the matter now shifts to the administrative law judge, who will issue a recommended decision, and once that happens, it goes back to the DEA so the agency can take final action. We still don't know the timeline, but completing the hearing represents yet another meaningful milestone in the push for federal cannabis reform. That momentum is already becoming visible in the capital markets. Trulieve, in June, became the first U.S. A cannabis company became the first of its kind to be traded on the New York Stock Exchange, following a reorganization of its overall operations centered on state-licensed medical cannabis. In addition, Clear Relief, Verano, and Ascend Wellness have each moved forward with efforts that could lead to their own listings on major U.S. exchanges. If more of these exchanges become accessible, the industry could attract a larger pool of institutional investors and gain access to more conventional forms of capital, which would be a positive development for everyone involved. Despite these advances, some operators are still facing difficulties. Last month, we made it public that Parallel failed to meet its lease obligations at two Florida properties we own. Our plan is to work with Parallel to manage a smooth handover of those properties, all while keeping every right and remedy the leases give us fully intact. On the state side, Virginia finally made a move that had been a long time coming, setting up a legal retail market for adult use, with sales at retail anticipated to kick off on July 1, 2027. In our view, this creates a significant growth opportunity for the tenants we serve and puts the state on track to rank among the most appealing cannabis markets worldwide. markets in the nation. With that said, I'll hand things over to Ben now so he can walk through more specifics regarding our leasing, disposition, and other investment activities. Ben?.
Appreciate that, Paul. Across the opening six months of the year, we signed new leases amounting to 389,000 square feet spanning five properties in California, Illinois, and Ohio. On top of that, we hold 488,000 square feet of agreements covering the four assets that were previously leased to Forefront Ventures. Those agreements still hinge on customary due diligence, which includes licensing and regulatory approvals, and we can't guarantee that these talks or negotiations will end in executed leases. As Paul outlined, we anticipate taking back our two Florida properties that parallel leases, which total 593,000 square feet. Florida continues to be the biggest medical cannabis market nationwide, backed by a wide patient base, robust consumer demand, and a restricted license framework. We think those fundamentals offer a solid basis for ongoing growth, with possible adult use legalization serving as a further long-term catalyst. We're hopeful that such market conditions will convert into significant demand for our facilities. We remain heartened not just by how much demand exists for our assets, but also by the capital-efficient way we've managed to re-tenant our properties. Given the roughly 877,000 square feet of gross leasing activity we've outlined, we project that average total leasing costs on these assets will come in under $5 per square foot. Moving to dispositions, in the quarter we completed an $88.5 million sale of our 389,000 square foot New York facility to Vireo Growth under a tenant purchase option. At closing, we got a down payment of roughly $39 million and extended about $49 million in seller financing carrying a 15% interest rate. We also completed the disposition of our land site in San Marcos, Texas. Plus we're under contract to sell two retail properties in Michigan and California. Each one is still subject to customary closing conditions and other contingencies. Along with the sale of a dispensary property in Arizona from earlier this year, these transactions show our continued strategy of opportunistically monetizing chosen assets and recycling capital throughout the portfolio. Shifting to investment activity this quarter, we keep carrying out our strategy of diversifying our platform and boosting our investments in the life science sector. To be specific, we fully funded the remaining $120 million on our $270 million commitment to IQHQ. As IQHQ noted in their June press release, IQHQ recently signed a long-term lease with advanced sale for the whole 128,000 square foot, one corporate drive building at Innovation Park, IQHQ's life science and advanced manufacturing campus in Andover, Massachusetts. Advance Cell, a clinical stage radiopharmaceutical company, stated in their June and July 2026 press releases that it recently wrapped up an oversubscribed $315 million Series D financing, and OneCorp Drive is anticipated to act as its manufacturing site within the United States as well as its global headquarters. The advanced cell lease comes on the heels of the 244,000 square foot deal IQHQ disclosed with Lila Sciences at its Alewife Park property in 2025, and together those two assets account for roughly 372,000 square feet of gross leasing activity since our initial investment in IQHQ was made. This wave of leasing arrives as we observe encouraging signals throughout the wider life sciences market. Fresh reports from CBRE and JLL show that leasing activity rose to around 3 million square feet across the major U.S. life science markets in the first quarter, which is above the 2025 quarterly average. In addition, per those reports, Boston, San Diego, and the Bay Area have together averaged 75 life science leases each quarter over the past two years, a 35% rise compared with pre-pandemic levels. Venture capital funding climbed 12% year-over-year, hitting $7.4 billion, which pushed funding across the last four quarters to its highest point since 2008. 2022, while biotech R&D employment hit a record after five straight months of growth; and even though vacancy is still elevated, the development pipeline has fallen over 85% from the 2023 peak, and roughly 72% of the pending new supply is pre-leased. The unleased supply pipeline now makes up less than 1% of the total existing life science inventory nationwide. Considered as a whole, these trends keep strengthening our confidence in the sector's long-term fundamentals.
Okay, I'll hand things over now to David. Thanks, Ben. Looking at the second quarter, our total revenues came in at $63.3 million, which compares with $69 million during the first quarter. The main factor behind that decline was lower payments collected from some tenants that had defaulted, though this was partly offset by scheduled rent increases under our contracts and additional revenue generated from leasing activity. Adjusted funds from operations for the quarter reached $53 million, or $1.83 per diluted share, versus $53.4 million, or $1.88 per diluted share, in the previous quarter, and the drop here was again caused by the same items I just referenced. Moving to capital markets, throughout the quarter we stayed focused on taking proactive steps to reinforce our balance sheet and handle our May debt maturity by executing a set of coordinated financing transactions. Over the quarter, we closed on close to 150 million of secured term loan financings across five distinct transactions, and we kept tapping the equity markets when opportunities arose, bringing in 35 million via our common stock ATM program and 21 million via our preferred stock ATM program. Along with cash we had on hand and what was available under our revolving credit facilities, these moves allowed us to fully repay our $291 million of notes that came due in May, removing a major debt maturity and making our balance sheet even stronger. Once that May bond maturity was paid off, and with our balance sheet in a solid position, we shifted our attention to growth. In June, we kicked off a convertible debt offering, and thanks to robust investor interest, we managed to close an upsized offering of $402.5 million of exchangeable notes maturing in 2029, priced at an appealing 6%. As part of that transaction, we also bought back roughly 80.5 million of our common stock. Some of the remaining net proceeds went toward paying down borrowings under our revolving credit facility, bringing that balance down and boosting our financial flexibility while supporting our long-term strategic growth. Because of all these financing activities, we finished the quarter with a strong, flexible balance sheet featuring total liquidity of $300 million, made up of cash on hand and availability under our revolving credit facilities. Our balance sheet credit metrics are still solid, with net debt to adjusted EBITDA at 1.7 times and net debt to total gross assets at 14%; we're confident that our conservative capital structure, diversified access to multiple capital markets, and ample liquidity leave us well positioned to support our existing portfolio and drive continued long-term accretive growth of the platform.
Hello there, and thanks so much for sending in your questions this afternoon. I realize the quarter was quite busy for all of you. Perhaps as a way to kick things off, what's the best way to frame how you're approaching putting that added liquidity to work and deciding where it goes? You brought up a few of the possibilities in life sciences. Clearly, you've got the legacy. see cannabis, so when we consider the sorts of opportunities you're identifying for deploying that capital, maybe you could offer a bit of commentary comparing those two sectors, and also whether you expect to see them arrive as bigger deployment chunks or whether they're showing up more dispersed across smaller ones. Thank you.
Absolutely. I believe that's an excellent way to begin, since it speaks to our conviction that we're now set up to grow, and it lets us capitalize on what we've already accomplished with the balance sheet, along with the work we've clearly done within the existing portfolio. Beyond that, the diversification we've been discussing over the past several quarters keeps moving along nicely. As you'll see, we fulfilled our acquisition commitment to IQ HQ — an extra amount I believe was 90 million, bringing our total commitment in the IQ HQ transaction to 270 million dollars — and with this most recent commitment producing a yield above 14%, we recognize the chance to capture those above-average returns while being strongly accretive to IIPR, still within the life science sector. So we're pressing ahead with our diversification initiative. That's essentially where we stand right now. Regarding how chunky these deals are, well, life science transactions tend to be rather sizable, which does suggest potentially chunky or large-scale investments ahead; even so, we're continuing to evaluate what we view as an improving situation.
Regarding the cannabis sector and where we might find chances to expand, I appreciate that, Kyle. That's genuinely useful. My second question concerns the older cannabis tenants we've had. Clearly, during the prior year, you all examined some of these and took a proactive kitchen-sink approach, along with certain tenant defaults, and conditions appear to be getting better, yet we obviously saw the parallel announcement come out. So I wanted to revisit that point regarding your remarks, and regarding how strongly positioned you are with the portfolio as it stands. Conditions appear to be getting better now with 280E. Taxes got better at least for medical, and possibly for adult use with phase two rescheduling. I wanted to get the wider picture regarding how at ease you are today with the cannabis portfolio moving forward. Thank you.
And, you know, I think you can — the parallel transaction, it was a restructuring that moved slowly, taking many years before it finally came to fruition. It got started, you know, we've been working through it for the last, I don't know, 3 or 4 years. And, you know, now it's finally culminated. Yes, we wound up with 2 very high quality assets down in Florida, which we believe is a strong, strong market; and we're already getting interest in those 2 assets. As for the rest of the portfolio, we believe the industry keeps improving. We certainly are — I feel very positive about the rescheduling, and hopeful that the further rescheduling process gets completed. Noting that everything takes much longer than all of us want or hope for, for the positive effects of those actions to occur. We are monitoring all of our tenants, on a quarterly basis and or more regularly. And we're doing our best to make sure we understand where all of our tenants sit; we believe our portfolio keeps strengthening and we're — and believe, and believe that the opportunity to take advantage of the rescheduling that's happening in the cannabis industry will, will, will, will show itself throughout this year and into 2027 and beyond.
All right, that's helpful context — I appreciate it. I'll rejoin the line now. Thanks a lot. Thank you, Aaron.
Good afternoon, everyone. The first thing I'd like to ask about is that property sale in St. Marcus. What I'm wondering is what shifted regarding the opportunity at that property,
especially now that Texas has its medical program finally getting underway? Hi Bill, Ben here. Changed isn't a word I'd use. What I mean is, that piece of land had no development on it. Parallel and we did that deal several years back. The improvements — the ones specific to cannabis — were never built at that site. So even though we view Texas as a fantastic opportunity, we saw a pretty long runway, you know, before we might have to put something up and get it approved. And recycling that capital right now into highly accretive deals like the IQHQ funding felt like a better use of it than pursuing a new development.
All right, so your thinking on taxes hasn't shifted at all? Correct. Okay. Next, Paul, you mentioned how capital markets now treat the industry in a different way — perhaps your tenants get treated somewhat differently, and maybe you do too. So theoretically speaking, given those regulatory changes, whose cost of capital stands to gain more, yours or your tenants'?
You know, what we can highlight immediately is this: on the tenant side, when Trulieve shows up listing on the New York Stock Exchange, had you predicted that 3 years ago, people would have thought we'd lost our minds. And then we see Curly, Verano, and Ascend all pursuing uplisting moves as well. You know, I believe that is the fastest route for those operators to reach the public capital markets. So for them that's a major plus, I think, and definitely for us since they're our credit tenants. I think our cost of capital, I think, benefits in 2 ways for sure. First, I think because of our diversification into the life science industry and non cannabis, when we look at lenders, they view us somewhat more favorably since we aren't in the cannabis space. So I think that diversification has produced a direct result. And I think too, you know, our access to lenders within the cannabis space will definitely get better once rescheduling happens.
Thanks. I appreciate it, Paul. And thank you, Ben. I'll relay that message. Thanks, Bill.
Hi, everyone. There's something I should probably confess. This is Tom Counterwood from BTIG. I appreciate you taking my questions. I wanted to ask about the leases you've executed. Looking at the quarter, based on our calculations, roughly nine properties had space that was re-leased, yet the tenants had not begun paying rent. I realize predicting when leases commence is difficult, but run rate revenues appear to be coming in above what we'd anticipate for this quarter. Could you provide a broad picture of what started in 2Q and what you anticipate under your base case for the remainder of this year?. Yes, hi Tom, Ben here. Regarding Q2 specifically, I wouldn't characterize anything as material that began during it, and I continue to believe that what we've talked about previously remains the correct framework, namely that you're looking at 9 to 12 plus months from when a lease is signed until abatement periods and licensing are completed. So considering the nearly 900,000 square feet across executed leases and the arrangements we have with Forefront, those remain the former Forefront assets. I believe that's still the proper approach for modeling it; this is only to clarify that point, Ben, because once more, if we remove the back rents paid by Forefront and PharmaCan and we remove some of the security deposits that you've folded into rental revenue, it still appears you're running roughly $2 million, perhaps $1.92 million greater quarter over quarter on a run rate basis. Is something else commencing, or is that simply a matter of the It's essentially a stable run rate, and consequently anything else you identify remains upside going forward.
Yes, Thomas, I believe David here, I would simply restate what Ben mentioned, that nothing material occurred during the quarter, so we're I'm glad to speak with you offline about this more. There's one additional item, if you're factoring it into the first quarter, we also had roughly a million and a half that came in from Global Flora. So I'm uncertain whether you're making an adjustment for that in your figures, but glad to talk about it Perfect. Thank you for that, David. Then the final one from me,.
Pharma can in New York and Pennsylvania — and I realize there's probably a limit on what you're able to discuss — but in the release, it really looked as though engagement has shifted when it comes to those two assets in particular. So could there be an opportunity there to perhaps push toward a resolution? I believe you'd noted before that an earlier LOI existed on the Montgomery, New York asset. Has that kind of change occurred, and how might it affect occupancy at those assets? Yes, hey Tom, it's Ben once more. Yes, I'd say the interest we've gotten in those two assets has made us happy. Nothing on the Moncrief has really shifted, as far as I can tell. That's still something we're grinding through. I believe we noted that we're aiming for a possible resolution in which we bring new tenants into those two properties, which would, you know, be a sign of further stabilizing the portfolio on top of the 900,000 square feet we've kept referencing. That's really all we can share on that right now. I appreciate it; and just one quick follow-up on that, Ben. You brought up the assets that were released. You brought up the Forefront assets that are waiting on the court's resolution. Do you have any other assets under LOI where you anticipate a formal lease being executed in the near term? Yes, I mean, there are a number of assets under LOI at differing stages of negotiation. You know, I believe we've discussed that in general terms, simply because of the uncertainty regarding timing and the diligence items still outstanding, and we really kind of centered our remarks today on the executed leases, the Forefront agreements that are in place. That adds up, again, to almost a million square feet in leasing activity within just those two buckets behind that. And again, throughout the portfolio, we've been quite pleased with how much demand we've seen for our assets. And our hope is that we can keep converting some of these and some of these conversations into additional gross leasing. the rest of 2026 and on into 2027; that's great. Thanks for all the answers, everyone.
Thank you, and thank you all for joining today. Thank you. Thanks to the team for the tremendous execution, not only on the balance sheet and on the portfolio, diversification program that we have in place; with that, we will close the meeting.
I'll bring things to a close. That wraps up the call for today. We appreciate your participation. You're free to leave the line now. This real-time transcript is produced automatically, with no person involved in creating or checking it.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Innovative Industrial Properties, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Innovative Industrial Properties, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.